NVAX — NOVAVAX INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1000694 ·
Last close
$8.86
Market Cap
$1.46B
52W High
$11.61
52W Low
$7.15
ADV30
3,706,936
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 56,698,000 | 42,452,000 | -54,906,000 | -53,387,000 | 955,575,000 | 191,458,000 | 1,146,282,000 |
| Mar 2026 | 139,514,000 | 108,819,000 | -15,430,000 | -9,491,000 | 1,043,162,000 | 228,363,000 | 1,187,924,000 |
| Dec 2025 | 147,139,000 | 125,035,000 | 15,037,000 | 17,527,000 | 1,176,512,000 | 240,634,000 | 1,304,265,000 |
| Sep 2025 | 70,445,000 | 48,949,000 | -80,980,000 | -202,379,000 | 1,179,889,000 | 268,023,000 | 1,336,561,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,556,000
Investing CF
$-33,309,000
Financing CF
$72,473,000
CapEx
$-6,063,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,631,026,000
Inventory
$10,006,000
Receivables
$18,739,000
ST Investments
$527,882,000
EBIT TTM
$-223,419,000
Pretax Income TTM
$-245,315,000
Interest Exp TTM
$21,896,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$413,796,000
EBITDA
$-101,552,000
Free Cash Flow
$153,394,432
Enterprise Value
$1,052,593,792
Total Cash
$719,340,032
Total Debt
$297,319,008
Shares Out
164,945,726
Trailing EPS
$-1.53
Book Value
$-1.16
ROE
—
ROA
-6.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,479,000 | 550,640,000 | 440,302,000 | 1,176,512,000 | 1,304,265,000 | — | -244,635,000 |
| Dec 2024 | 682,162,000 | -248,931,000 | -187,499,000 | 1,560,418,000 | 2,184,259,000 | — | -87,263,000 |
| Dec 2023 | 556,382,000 | -566,511,000 | -545,062,000 | 1,797,490,000 | 2,514,417,000 | — | -713,967,000 |
| Dec 2022 | 1,598,951,000 | -644,736,000 | -657,939,000 | 2,258,679,000 | 2,892,757,000 | — | -415,937,000 |
TTM Snapshot
Revenues TTM
$1,184,919,000
NetIncome TTM
$-743,120,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,418,000
Forward EPS
$-0.61
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $8.86 · call volume: 212 · put volume: 2,027
Expected Move to 2027-01-15:
±$3.15
(35.55%) —
implied range
$5.71 –
$12.01
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc | $1.42B | $14.83 | — |
| SLBT | SL Science Holding Ltd | $1.52B | $2.71 | — |
| CGEM | Cullinan Therapeutics, Inc. | $1.40B | $21.82 | — |
| REPL | Replimune Group, Inc. | $1.39B | $14.71 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.54B | $104.94 | — |
News headlines (Yahoo Finance, 1h cache)
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
2026-08-22 07:53 · Yahoo
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
2026-08-21 17:01 · Yahoo
Novavax (NVAX) Shares Skyrocket, What You Need To Know
2026-08-19 21:50 · Yahoo
Novavax Q2 Earnings Call Highlights
2026-08-07 06:04 · Yahoo
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...
2026-08-06 23:19 · Yahoo
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals
2026-08-06 21:29 · Yahoo
Are Medical Stocks Lagging Novavax (NVAX) This Year?
2026-08-06 13:40 · Yahoo
Novavax (NASDAQ:NVAX) Exceeds Q2 CY2026 Expectations
2026-08-06 13:18 · Yahoo
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-06 12:00 · Yahoo
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
2026-08-20 14:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.